Suscriptores   Asóciese  
Textos Completos Autorizados
EFICACIA Y SEGURIDAD DE DOS FORMULACIONES DE ACIDO MICOFENOLICO EN NIÑOS CON TRASPLANTE RENAL

v-estudie-lo-mejor.gif
Expertos Invitados





EFICACIA Y SEGURIDAD DE DOS FORMULACIONES DE ACIDO MICOFENOLICO EN NIÑOS CON TRASPLANTE RENAL

(especial para SIIC © Derechos reservados)
La conversión de micofenolato de mofetilo a mcofenolato sódico con capa entérica es eficaz y segura en niños con trasplante renal. Los síntomas gastrointestinales son menores con la formulación de capa entérica.
Autor:
Mara Medeiros
Columnista Experta de SIIC

Institución:
Hospital Infantil de México Federico Gómez

Artículos publicados por Mara Medeiros
Coautor
Mara Medeiros* 
Dra., Hospital Infantil de México Federico Gómez, México, México*
Aprobación
9 de Noviembre, 2010 		Primera edición
17 de Noviembre, 2010 		Segunda edición, ampliada y corregida
7 de Junio, 2021

EFICACIA Y SEGURIDAD DE DOS FORMULACIONES DE ACIDO MICOFENOLICO EN NIÑOS CON TRASPLANTE RENAL


Artículo completo
(castellano)
Extensión:  +/-3.03 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes
Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Nefrología y Medio Interno, Trasplantes
Relacionadas: Farmacología, Inmunología, Medicina Farmacéutica, Pediatría



Comprar este artículo
Extensión: 3.03 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Mara Medeiros, Laboratorio de Investigación en Nefrología y Metabolismo Mineral Hospital Infantil de México Federico Gómez, 06720, Dr. Marques 162 Col. Doctores, Mexico DF, México
Bibliografía del artículo
Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80:S181-90, 2005.
Ettenger R, Bartosh S, Choi L, Zhu W, Niederberger W, Campestrini J et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr Transplant 9:780-7, 2005.
Laouad I, Halimi JM, Buchler M, Al-Najjar A, Chatelet V, Nivet H et al. Recipient age and mycophenolate mofetil as the main determinants of outcome after steroid withdrawal: analysis of long-term follow-up in renal transplantation. Transplantation 80:872-4, 2005.
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46:13-58, 2007.
Hesselink DA, Van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 78:317-21, 2005.
Van Hest RM, Mathot RA, Vulto AG, Ijzermans JN, Van Gelder T. Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view. Ther Drug Monit 28:31-4, 2006.
Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13:759-68, 2002.
Bremer S, Vethe NT, Rootwelt H, Bergan S. Expression of IMPDH1 is regulated in response to mycophenolate concentration. Int Immunopharmacol 9:173-80, 2009.
Sombogaard F, Peeters AM, Baan CC, Mathot RA, Quaedackers ME, Vulto AG et al. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. Ther Drug Monit 31:549-56, 2009.
Bolin P, Tanriover B, Zibari GB, Lynn ML, Pirsch JD, Chan L et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 84:1443-51, 2007.
Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 24:645-63, 2001.
Van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 80:S244-53, 2005.
Nart A, Sipahi S, Aykas A, Uslu A, Hoscoskun C, Toz H. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients. Transplant Proc 40:189-92, 2008.
United States Patent. Patent Number 6,306,900 B1. Enteric coated pharmaceutical compositions. Available from: www.google.com.mx/patents?id=DA8IAAAAEBAJ&printsec=claims&zoom#v=onepage&q=&f=false. Accesed January, 25, 2010.
Budde K, Knoll G, Curtis J, Chan L, Pohanka E, Gentil M et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 66:103-11, 2006.
Zimmerhackl LB, Jungraithmayr T, Wiesmayr S, Filler G. Myfortic in pediatric transplantation. Pediatr Transplant 12:614-6, 2008.
Pape L, Ahlenstiel T, Kreuzer M, Ehrich JH. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant 12:640-2, 2008.
Niaudet P, Charbit M, Loirat C, Lapeyraque AL, Tsimaratos M, Cailliez M et al. Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients. Pediatr Nephrol 24:395-402, 2009.
Machnicki G, Pefaur J, Gaite L, Linchenco AM, Raimondi C, Schiavelli R et al. Gastrointestinal (GI)-Specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American cohort. Health Qual Life Outcomes 6:53, 2008.
Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic kidney disease. Pediatr Nephrol 22:1839-48, 2007.
Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 353:2342-51, 2005.
Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8:753-60, 2008.
Ferraris JR, Tambutti ML, Prigoshin N, Grosman M, Cardoni RL. Conversion from mycophenolate mofetil to delayed formulation in pediatric renal transplantation: Higher mycophenolic acid predose level but no changes in the immune biomarkers. Pediatr Transplant 2009.
Kiberd BA. Post-transplant erythrocytosis: a disappearing phenomenon? Clin Transplant 2008.
Heller T, Geide A, Bonitz U, Wegner U, Grone HJ, Armstrong VW et al. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy in a rat model. Transplantation 85:739-47, 2008.
Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 85:1120-4, 2008.
Budde K, Tedesco-Silva H, Pestana JM, Glander P, Neumayer HH, Felipe CR et al. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther Drug Monit 29:381-4, 2007.
Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 85:1675-85, 2008.
Bunnapradist S, Lentine KL, Burroughs TE, Pinsky BW, Hardinger KL, Brennan DC et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 82:102-7, 2006.
Davies NM, Grinyo J, Heading R, Maes B, Meier-Kriesche HU, Oellerich M. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant 22:2440-8, 2007.
Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 39:88-93, 2007.
Yang JW, Lee PH, Hutchinson IV, Pravica V, Shah T, Min DI. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther Drug Monit 31:542-8, 2009.
Título español
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

  English title
  Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia
Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517